## RECEIVED AT DRUG SAFETY SURVEILLANCE

McNEIL CONSUME FORT WASHI

Page \_\_

| A. Patient information  |  |                     |          |  | C. Suspect medication(s)  |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|---|--|---------------------|----------|--|---|--|-----------------|---------------------------|-------------------------------|------------|--|--|--|--|--|--|--------|--|--|--|
| 1. Patient identifier 2. Age at time 3. Sex 4. Weight   |  |                     |          |  | Name (give labeled strength & mfr/labeler, if known)                            |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|   | of event:<br>52 yrs (X) female unk lbs |                     |          | #1 hydrocodone/acetaminophen 10/650 mg |   |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| Case 244  | Or                                     |                     |          | or                                     | #2  |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| In confidence   | of birth:                              |                     | ()male   | kgs                                    | 2. Dose, frequency & rou  | te used.   | 3. Therepy date | s (if unk                 | nown, give duration)          |            |  |  |  |  |  |  |        |  |  |  |
| B. Adverse event or product problem   |  |                     |          |  | from/to (or be  |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| 1. X Adverse event and/or Product problem (e.g., defects/malfunctions)  |  |                     |          |  | #1 unknown dose, po   | #1 unknown dose, po #1 unknown dates or duration |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| 2. Outcomes attributed to adverse event   |  |                     |          |  | #2 4. Diagnosis for use (indication)   5. Event absted after use                |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| ( ) disability  |  |                     |          |  | 1 · · · · · · · · · · · · · · · · · · ·   |  |                 |                           | ed or dose reduced            |            |  |  |  |  |  |  |        |  |  |  |
| (X) death unknown () congenital anomaly   |  |                     |          |  | #1 intentional misuse   |  |                 | l., , ,                   | Yes ( ) No (X) N/A            |            |  |  |  |  |  |  |        |  |  |  |
| ( ) life-threatening ( ) required intervention to prevent permanent impairment/damage   |  |                     |          |  | #2  |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| (x) hospitalization - initial or prolonged  |  |                     |          |  | 6. Lot # (if known) 7. Exp. date (if known)                                     |  |                 | #2 ( )                    | Yes ( ) No ( ) N/A            |            |  |  |  |  |  |  |        |  |  |  |
| (1) other: 3. Date of event 4. Date of this report  |  |                     |          | #1 Unknown                             | #1 Unknown  |  |                 | 8. Event reappeared after |                               |            |  |  |  |  |  |  |        |  |  |  |
| unknown   | ,                                      | •                   | 02/06/98 |  | #2  | #2   |                 | reintr                    | oduction                      |            |  |  |  |  |  |  |        |  |  |  |
| (mo/day/yr)   |  | imo/day/yri ,       |          |  |   | <u>.                                    </u>     |                 | #1 ()                     | Yes ( ) No (X) N/A            |            |  |  |  |  |  |  |        |  |  |  |
| 5. Describe event or problem  |  |                     |          |  | 9. NDC # - for product problems only (if known)                                 |  |                 | l                         |                               |            |  |  |  |  |  |  |        |  |  |  |
| Case # 244 received from the 1996 case fatality data.   |  |                     |          |  | #2 ( ) Yes ( ) No (   |  |                 |                           | Yes ( ) No ( ) N/A            |            |  |  |  |  |  |  |        |  |  |  |
| See attached case report form provided by   |  |                     |          |  | 10. Concomitant medical products and therapy dates (exclude treatment of event) |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | See attached case report form provided by                                       |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  |   |  |                 |                           |                               | Ļ          |  |  |  |  |  | 1. Contact office - name/address (& mfring site for devices) 2. Phone number |        |  |  |  |
|   |  |                     |          |  |   |  |                 |                           |                               | FE310 (EF) |  |  |  |  | HcNeil Consumer Products Company  Medical Affairs  7050 Camp Mill Road  Ft. Washington, PA 19034  ( ) foreign  ( ) study |  |        |  |  |  |
|   |  |                     |          |  |   |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
| İ   |  |                     |          |  | <u> </u>  |  |                 |                           | ( ) consume                   |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | 4. Date received by manu  | facturer   5                                     |                 |                           | health<br>(x) professional    |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          | (ma/dm//yr) 01/30/98 (A) NDA # 17-     |   |  | 52              | ( ) user facility         |                               |            |  |  |  |  |  |  |        |  |  |  |
| <b>i</b> .  |  |                     |          |  | 6. If IND, protocol #   |  | IND #           |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | O. 11 M.D., process. 2  |  | PLA #           |                           | company<br>( ) representative |            |  |  |  |  |  |  |        |  |  |  |
| 6. Relevant tests/lab   | oratory data,                          | including dates     |          |  | 1   | İ  | pre-1938 (      | ) Yes                     | ( ) distributor               |            |  |  |  |  |  |  |        |  |  |  |
| See attached case report form provided by   |  |                     |          |  | 7. Type of report   |  | отс             |                           | ( ) other:                    |            |  |  |  |  |  |  |        |  |  |  |
|   | •                                      |                     |          |  | (check all that apply)  |  |                 | ) Yes                     | · ·                           |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | ( ) 5-day (X) 15-day  | 18.  | Adverse event   | term(s)                   | <u> </u>                      |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | ( ) 10-day ( ) periodi  |  | OVERDOSE        |                           | OHA                           |            |  |  |  |  |  |  |        |  |  |  |
| 1   |  |                     |          |  | (X) Initial ( ) follow-   | ~~   | HYPOTENSION     | _                         | CIDOSIS LACTIC                |            |  |  |  |  |  |  |        |  |  |  |
| 1   |  |                     |          |  | 9. Mfr. report number   |  | LIVER FAILU     |                           | PHEA                          |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | 0929724A  |  | SHOCK           |                           | EATH                          |            |  |  |  |  |  |  |        |  |  |  |
| <ol> <li>Other relevant history, including preexisting medical conditions (e.g., allergies,<br/>race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)</li> </ol> |  |                     |          |  | E. Initial reporte  | r  |                 |                           | <b>-</b> -                    |            |  |  |  |  |  |  |        |  |  |  |
| See attached case report form provided by   |  |                     |          |  | 1. Name, address & phone #  |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | MD Centers  |  |                 |                           |                               |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  |   |  |                 |                           |                               |            |  |  |  |  | Sui te <b>lle le le</b>  |  | Avenue |  |  |  |
| 1   |  |                     |          |  |   |  |                 | <del></del>               |                               |            |  |  |  |  |  |  |        |  |  |  |
|   |  |                     |          |  | 2. Health professional?   | 3. Occupat                                       | ion             |                           | reporter also<br>eport to FDA |            |  |  |  |  |  |  |        |  |  |  |
|   |  | nission of a report |          |  | (X) Yes ( ) No  | physic   | cian            | $\bigcirc$                | Yes ( ) No (X) Unk            |            |  |  |  |  |  |  |        |  |  |  |



distributor, manufacturer or product caused or contributed to the event.





## FATALITY: 1996



Case Number:

244

Age:

52 yrs

Substances:

Acetaminophen/hydrocodone

Chronicity:

Chronic

Route:

Ingestion

Reason:

Int misuse

Pre-Hospital Arrest? No

A 52 yo disabled (chronic back pain) white female was brought unresponsive into the ED of a rural hospital. She had been found unconscious by her family next to bottles of hydrocodone/acetaminophen 10/650 mg (#50) and carisoprodol 350 mg #(100).

An acetaminophen level was 30 mcg/ml, drawn at a time unknown in relation to ingestion. The patient was profoundly acidotic, with a ph of 6.85. Naloxone was administered to a total dose of 8.8 mg IV without effect.

On transfer to a referral hospital, the patient was comatose and had the following vital signs: BP 75/43 mm Hg, P 125 BPM, R 27/min and T (rectal) was 97.8°. An initial blood gas showed: pH 6.95, pCO2 14, and bicarbonate 3 mmol/L. Blood lactic acid level was 25.9 mg/dL. Urine toxicology screen was positive for opiates and barbiturates. Additional lab work included a sodium of 159 mmol/L, potassium of 3.6 mmol/L, chloride of 115 mmol/L and bicarbonate of (5 mmol/L). Prothrombin time was 35.7 seconds and ammonia was 225 umol/L (nl = 11-35).

The patient was treated with endotracheal intubation, plus aggressive treatment of fluid/electrolyte and acid-base abnormalities. She was given a loading dose of mucomyst. She experienced rapid progression of multi-system organ failure which culminated in her demise within 24 hours of admission.

Cause of death was attested to be by her attending physician: acute polydrug overdose with lactic acidosis, hepatic failure, respiratory failure and cardiogenic shock. Although the poisoning was a polydrug overdose, the most important event leading to death was considered to be delayed presentation of acetaminophen-induced liver failure.